As previously reported, on December 12, 2017, the Ontario Legislature passed the Strengthening Quality and Accountability for Patients Act, 2017, which enacts or amends 10 statutes including the Health Sector Payment Transparency Act, 2017 (Transparency Act). When in force, the Transparency Act will require disclosure of financial relationships between pharmaceutical or medical device manufacturers (among other “payors”) and health care professionals (among other “recipients”). On February 21, 2018, the Ontario Ministry of Health and Long-Term Care published for consultation proposed regulations under the Transparency Act. The proposed regulations specify: what constitutes a “transfer of value” that must be reported; who qualifies as an “intermediary” or a “recipient” of a “transfer of value”; additional categories of “payors”; what thresholds and exemptions exist to the reporting requirements; the manner and frequency of reporting; and the process for correcting posted information. The consultation period ends April 6, 2018.
Related Publications & Articles
-
Medical Devices updates: Phase II consultation on Medical Devices Regulations amendments, medical device licences guidance and IMDRF table of contents guidance
On November 17, 2025, Health Canada proposed Phase II amendments to the Medical Devices Regulations (MDR). The first phase of amendments came into force on December 14, 2024 and relate to recalls, mod...Read More -
Proposal for modernizing clinical trial framework aims to improve access to new and innovative therapies in Canada
On December 20, 2025, Health Canada launched a consultation on modernizing the framework for clinical trials involving drugs for human use, including pharmaceuticals, biologics, radiopharmaceuticals, ...Read More -
Health Canada consultation on two draft guidance documents on terms and conditions for human and veterinary drugs and drug submissions based on promising evidence of clinical efficacy
As previously reported, in December 2024, Health Canada published its agile licensing amendments to the Food and Drug Regulations.Read More
